Honolulu, HI, United States
Honolulu, HI, United States

Time filter

Source Type

Patent
Tissue Genesis, Inc | Date: 2015-09-28

The present invention provides automated devices for use in supporting various cell therapies and tissue engineering methods. The present invention provides an automated cell separation apparatus capable of separating cells from a tissue sample for use in cell therapies and/or tissue engineering. The cell separation apparatus can be used in combination with complementary devices such as cell collection device and/or a sodding apparatus to support various therapies. The automated apparatus includes media and tissue dissociating chemical reservoirs, filters, a cell separator and a perfusion flow loop through a graft chamber which supports a graft substrate or other endovascular device. The present invention further provides methods for using the tissue grafts and cell samples prepared by the devices described herein in a multitude of therapies including revascularization, regeneration and reconstruction of tissues and organs, as well as treatment and prevention of diseases.


Grant
Agency: Department of Defense | Branch: Army | Program: SBIR | Phase: Phase I | Award Amount: 99.80K | Year: 2014

Tissue Genesis (TGI) is proposing to develop a highly portable, easy to use, low-cost, point-of-care, adipose-derived stem cell (ASC) isolation device that fully integrates the process from fat extraction to cell product. This next generation system addresses current technology limitations including: sterility breaks, acquisition and process time, complexity of operation, and cost. The convenient and rapid recovery of millions of regenerative cells will fill the unmet need as a readily available source of adult stem cells for therapeutic use across multiple military trauma needs, such as wound healing, tissue and nerve repair, orthopedic injury repair, plastics and aesthetics, ophthalmology, and otolaryngology. The proposed system addresses current technology, cost, and convenience shortfalls and allows for a rapid translation of regenerative stem cell therapeutics into the clinic.


Grant
Agency: Department of Defense | Branch: Army | Program: SBIR | Phase: Phase II | Award Amount: 997.50K | Year: 2015

Tissue Genesis (TGI) is developing a low-cost, highly portable, fully automated adipose-derived stem cell (ADSC) isolation device that addresses current technology limitations including sterility breaks, process time, complexity, and cost. It is an outpatient cell recovery system that prioritizes cell yield, viability, and purity by using novel processes with improved biomaterials. The Phase I SBIR has successfully shown the feasibility of the new technologies being employed in the device, and has defined the path for prototype development. Phase II will take a prototype through iterative design and testing cycles, arriving at a matured product design that will produce high purity ADSCs suitable for all clinical applications. By leveraging ongoing FDA IDE trials and approvals, subsequent efforts will be structured to demonstrate equivalence with the companys industry leading TGI Icellator Cell Isolation System, thereby fast-tracking commercial introduction and use of the new device. In aggregate, this development will produce a commercially viable device that makes access to ADSCs simple, rapid, and cost effective, thereby making therapies using adult stem cells feasible in mainstream medicine for both warfighters and civilians worldwide.


Patent
Tissue Genesis, Inc | Date: 2013-03-15

Cell aggregate forming chambers are described, suitable for automated loading and unloading, where the airtight chamber contains a mold with a plurality of cavities, where there is an inlet and an outlet for cells, and where air is filtered before it comes into the chamber. Method of using the chamber include injecting cells into the chamber, providing conditions where the cells may grow to form cell aggregates, and extracting the cell aggregates through a cell outlet.


Patent
Tissue Genesis, Inc | Date: 2014-03-20

Devices and methods are provided for processing adipose tissue with a hand-held device. This device may include a processing chamber, a cannula, a vacuum source, a digestion area, and a product cell concentration chamber.


The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. Another aspect provides a composition comprising an engineered corpus cavernosum tissue comprising SVF cells and corpus cavernosum cells, wherein the SVF cells can be mixed with or encasing the corpus cavernosum cells, and methods of uses thereof, for example in method for the treatment of impotence and erectile dysfunction and/or enhance or contruct a penis. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.


Devices and methods are provided for aspirating adipose tissue with a portable device. This device may include a processing chamber, a cannula, a vacuum source, a filter or screen for separating connective tissue strands from adipose tissue, a digestion area, and a product cell concentration chamber.


The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. Another aspect provides a composition comprising an engineered corpus cavernosum tissue comprising SVF cells and corpus cavernosum cells, wherein the SVF cells can be mixed with or encasing the corpus cavernosum cells, and methods of uses thereof, for example in method for the treatment of impotence and erectile dysfunction and/or enhance or construct a penis. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.


Patent
Tissue Genesis, Inc | Date: 2014-09-16

Cell delivery matrices and methods for facilitating local delivery of adipose derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patients own body. The cell delivery matrix may be biocompatible and semi-permeable. The cell delivery matrix used in the methods of the invention may be comprised of any degradable, bioabsorbable or non-degradable, biocompatible polymer. Regenerative therapies comprising implanting in the subject cell delivery matrices localizing adipose derived endothelial cells are described. The cell delivery matrices maintain the adipose derived endothelial cells at the target for a therapeutically effective amount of time. The adipose derived endothelial cells can be allogenic or syngenic to the subject. The endothelial cells may be delivered alone or in combination with other therapeutic agents.


Patent
Tissue Genesis, Inc | Date: 2014-09-16

Cell delivery matrices and methods for facilitating local delivery of adipose derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patients own body. The cell delivery matrix may be biocompatible and semi-permeable. The cell delivery matrix used in the methods of the invention may be comprised of any degradable, bioabsorbable or non-degradable, biocompatible polymer. Regenerative therapies comprising implanting in the subject cell delivery matrices localizing adipose derived endothelial cells are described. The cell delivery matrices maintain the adipose derived endothelial cells at the target for a therapeutically effective amount of time. The adipose derived endothelial cells can be allogenic or syngenic to the subject. The endothelial cells may be delivered alone or in combination with other therapeutic agents.

Loading Tissue Genesis, Inc collaborators
Loading Tissue Genesis, Inc collaborators